Screenshot

Atelerix appoints new chair and non-executive director to drive global expansion

Ella Day | August 13, 2025 | Appointment | Biotech/start-up, Sales and Marketing Atelerix, Corporate, non-executive director 

UK-based biotech company, Atelerix, has appointed Sunil Shah as chair of the board and Catherine Elton as non-executive director as it prepares for global commercial scale-up of its hydrogel-based, non-cryogenic cell preservation technology.

Shah, CEO of o2h Ventures, brings more than 20 years’ experience founding, scaling and investing in life sciences companies. He has served on the boards of multiple biotech ventures and is a non-executive director of the UK BioIndustry Association. His commercialisation expertise aligns with Atelerix’s goal to develop biological material preservation and transport.

Elton, currently chief business officer at Axol Biosciences, has over two decades of scientific and commercial leadership in the life sciences. She founded Qkine, a spin-out of the University of Cambridge that manufactures bioactive proteins. Previously, she held senior roles at Abcam where she scaled R&D and manufacturing operations.

Advertisement

Shah commented: “I am excited to join the board and help guide the next stage of growth.”

CEO Alastair Carrington added: “Catherine and Sunil are widely regarded for their scientific expertise and track record in company building. Their support will be invaluable as we expand internationally.”

Atelerix’s hydrogel technology supports the storage and transport of cells, tissues and viruses at room temperature for up to two weeks, eliminating the need for cold-chain logistics, which can be costly.

Ella Day

13/8/25

Related Content

No items found
The Gateway to Local Adoption Series

Latest content